GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (OTCPK:OPGN) » Definitions » WACC %

OpGen (OPGN) WACC % :2.97% (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OpGen WACC %?

As of today (2024-12-14), OpGen's weighted average cost of capital is 2.97%%. OpGen's ROIC % is -44.00% (calculated using TTM income statement data). OpGen earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


OpGen WACC % Historical Data

The historical data trend for OpGen's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen WACC % Chart

OpGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.53 2.37 2.23 12.23 10.24

OpGen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.21 10.24 7.04 5.47 2.35

Competitive Comparison of OpGen's WACC %

For the Medical Devices subindustry, OpGen's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's WACC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's WACC % distribution charts can be found below:

* The bar in red indicates where OpGen's WACC % falls into.



OpGen WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, OpGen's market capitalization (E) is $11.176 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2024, OpGen's latest one-year quarterly average Book Value of Debt (D) is $10.8728 Mil.
a) weight of equity = E / (E + D) = 11.176 / (11.176 + 10.8728) = 0.5069
b) weight of debt = D / (E + D) = 10.8728 / (11.176 + 10.8728) = 0.4931

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.395%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. OpGen's beta is 0.03.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.395% + 0.03 * 6% = 4.575%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2024, OpGen's interest expense (positive number) was $0.144 Mil. Its total Book Value of Debt (D) is $10.8728 Mil.
Cost of Debt = 0.144 / 10.8728 = 1.3244%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -9.399 = 0%.

OpGen's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.5069*4.575%+0.4931*1.3244%*(1 - 0%)
=2.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OpGen  (OTCPK:OPGN) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, OpGen's weighted average cost of capital is 2.97%%. OpGen's ROIC % is -44.00% (calculated using TTM income statement data). OpGen earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

OpGen Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
Yvonne Schlaeppi director 600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher officer: Chief Operating Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber officer: Chief Finanical Officer MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht director, officer: Chief Executive Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones director, officer: Chief Executive Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation 10 percent owner MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro officer: Chief Information Officer C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec officer: Chief Financial Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc 10 percent owner P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea director 6480 DOBBIN ROAD, COLUMBIA MD 21045

OpGen Headlines

From GuruFocus

Q2 2022 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q4 2020 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q2 2023 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q4 2022 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2023 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q2 2019 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q2 2021 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q1 2022 OpGen Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024